Hematologic Malignancy
Secondary Acute Myeloid Leukemia
CI-CAN-00001489Explore in graph →
Hematologic46 active trials2 approved drugs
- NCIt
- C25765
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001489Explore in graph →
Clinical trials
212 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02530034 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | active not recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05139004 | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03041688 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04190550 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06325748 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | active not recruiting | Phase 1 | 21 | Senti BiosciencesINDUSTRY | 2 | Feb 12, 2026 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials